BRDT and ovarian carcinoma: In primary human ovarian cancer cells (“pOC-1/-2/-3/-4”), transfection of lentiviral CRISPR/Cas9-BRDT-KO construct (with “sgRNA-1”) depleted BRDT mRNA (Fig. 4I), thereby resulting in viability reduction (Fig. 4J) and proliferation inhibition (Fig. 4K).